Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Drak2 is not required for tumor surveillance and suppression.

Edwards, Benjamin A; Harris, Tarsha L; Floersh, Helen; Lukens, John R; Zaki, Md Hasan; Vogel, Peter; Kanneganti, Thirumala-Devi; Bui, Jack D; McGargill, Maureen A.
Int Immunol; 27(3): 161-6, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25568303
Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2 (-/-) mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.
Selo DaSilva